Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22436595 | 0.85 | DUT (0.31) | DUTPIM1PIM2 | |
| SCHEMBL30688490 | 0.85 | DUT (0.31) | DUTPIM1PIM2 | |
| SCHEMBL333905 | 0.83 | TAAR1 (0.46) | IDO1 | |
| SCHEMBL408605 | 0.82 | TAAR1 (0.40) | IDO1DUT | |
| SCHEMBL6490220 | 0.81 | IDO1 (0.48) | IDO1 | |
| SCHEMBL30932446 | 0.81 | IDO1 (0.38) | IDO1PIM1PIM2 | |
| SCHEMBL30932445 | 0.81 | IDO1 (0.38) | IDO1PIM1PIM2 | |
| SCHEMBL3863346 | 0.79 | HTR1D (0.33) | DUT | |
| SCHEMBL1641298 | 0.79 | CA12 (0.35) | DUT | |
| SCHEMBL12078265 | 0.79 | IDO1 (0.38) | IDO1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024531-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3710457-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3710457-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024531-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | IDO1 1701/4885DUT 3471/4885PIM1 3019/4885 |
| US-20230133165-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | IDO1 1701/4885DUT 3471/4885PIM1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.